Time spent on erythropoietin stimulating agents administration in hemodialysis centers in Panama: a time and motion study

Figures & data

Figure 1. Mean active HCP time per patient per administration by tasks. Abbreviation. Diff, difference.

Table 1. Mean active healthcare professional time (HCP) per patient per session.

	Epoetin alfa IV (min)	CERA IV (min)	Task time Epoetin alfa IV (as % of average total time)	Task time CERA IV (as % of average total time)
Preparation	5.06	1.83	65%	33%
Distribution	0.25	0.49	3%	9%
Injection	0.26	0.98	3%	18%
Record-keeping	2.23	2.17	29%	40%
Total average time per ESA administration	7.81	5.47	100%	100%

Abbreviation. CERA, Continuous Erythropoietin Receptor Activator; ESA, Erythropoietin Stimulating Agent.

Figure 2. Estimated HCP costs per patient per administration (a), HCP costs per patient per year (b), estimated consumables costs during erythropoietin-stimulating agent administration per patient per year (c), and estimated HCP cost savings if a center switches from Epoetin Alfa to CERA for 1 year (US Dollars year 2018).